Silent in one assay, potent in another: VHHs against CDK2/CycE1
A joint Isogenica and Axxam case study profiled 192 VHHs against CDK2/CycE1 in functional assays. It found binders that block the target in two distinct ways, including one that a binding screen alone would have missed.
Rational VHH Humanisation: Keeping the binder you started with
Isogenica's latest case study shows how a structure-guided, iterative approach to VHH humanisation can push nanobodies to 80%+ human-likeness while retaining antigen binding, expression and stability, avoiding the common pitfall of trading away a good binder's properties in pursuit of sequence identity alone.
Crossing the Blood-Brain Barrier: Why Natural Transport Mechanisms Are the Smarter Route
Most biologics and even small molecules fail to cross the blood-brain barrier, leaving CNS drug delivery a persistent bottleneck. Isogenica's latest short video looks at why researchers are turning to the brain's own transport systems as a more promising path in.
Solving LNP's Liver Problem: Why Targeting Is the Next Frontier in RNA Delivery
Lipid nanoparticles have powered the RNA medicine revolution, but their default tendency to accumulate in the liver limits use beyond hepatic disease.
Webinar: When Hits Don’t Translate – Challenging Membrane Targets from GPCRs to CD3–TCR
How target presentation and environment shape epitope access, selection outcomes, and functional screening.
Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies
Isogenica Ltd., The VHH Company™, today announced an antibody discovery agreement with Cerberus Therapeutics to support the development of targeted immune-modulating therapies using single-domain antibodies. This agreement brings together Cerberus’s KappaLink™ platform — designed to engage Fc receptor-positive (FcR+) effector cells via circulating immunoglobulins — with Isogenica’s expertise…
From Hit to Clinic: Isogenica and Charles River Collaborate to Accelerate Next-Generation Peptide and VHH Discovery
Every breakthrough begins with discovery. Isogenica, a leader in synthetic VHH antibody and peptide discovery, has announced a collaboration with Charles River, a leading, global provider of drug discovery, development, and manufacturing solutions, to help biotech companies streamline discovery and accelerate progress toward clinic-ready therapeutics. This collaboration unites Isogenica’s…
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs).
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay capabilities with unique antibody discovery solutions for biotechnology and pharmaceutical clients.